Tuberous sclerosis historical perspective: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Tuberous sclerosis}} {{CMG}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==Historic...")
 
 
(11 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Tuberous sclerosis}}
{{Tuberous sclerosis}}
{{CMG}}
{{CMG}} {{AE}} {{Jose}}


Please help WikiDoc by adding content here. It's easy!  Click  [[Help:How_to_Edit_a_Page|here]] to learn about editing.
== Overview ==
Tuberous sclerosis is a disease first described in the 19th century. The brain changes were hypothesized to be the cause of the [[epilepsy]] and [[mental retardation]] only in 1880.


==Historical Perspective==
==Historical Perspective==
The name, composed of the Latin ''tuber'' (swelling) and the Greek ''skleros'' (hard), refers to the [[pathological]] finding of thick, firm and pale [[gyrus|gyri]], called "tubers", in the brains of patients [[postmortem]].  These tubers were first described by [[Désiré-Magloire Bourneville]] in 1880; the cortical manifestations may sometimes still be known by the [[eponym]] Bourneville's disease.
[[Image:Désiré-Magloire Bourneville.jpg|thumb|left|Désiré-Magloire Bourneville]]
Tuberous sclerosis first came to medical attention when dermatologists described the distinctive facial rash (1835 and 1850).  A more complete case was presented by [[Friedrich Daniel von Recklinghausen|von Recklinghausen]] (1862) who identified heart and brain tumours in a newborn that had only briefly lived.  However, [[Désiré-Magloire Bourneville|Bourneville]] (1880) is credited with having first characterized the disease, coining the name ''tuberous sclerosis'', thus earning the [[eponym]] Bourneville's disease.  The neurologist [[Heinrich Vogt|Vogt]] (1908) established a diagnostic triad of epilepsy, idiocy, and adenoma sebaceum (an obsolete term for facial angiofibroma).<ref name="TSC-history">Curatolo (2003), chapter: "Historical Background".</ref>


Symptoms were periodically added to the clinical picture. The disease as presently understood was first fully described by [[Manuel Rodríguez Gómez|Gomez]] (1979).  The invention of [[Medical ultrasonography|medical ultrasound]], [[computed tomography|CT]] and [[magnetic resonance imaging|MRI]] has allowed physicians to examine the internal organs of live patients and greatly improved diagnostic ability.  
* Tuberous Sclerosis was described as a specific disease in the 19th century, being initially referred to [[adenoma sebaceum]], epiloia, [[Pringle's disease]] or [[Bourneville's disease]].
* Rayer, a French [[dermatologist]], was the one to first describe the disease and the fibrovascular papules that characterize it, making illustrations of it.
* In 1850 the first written report of tuberous sclerosis appeared in "Vitiligoidea", published by Addison and Gull. It was not recognized as a distinct disease but was classified as "vitiligoidea tuberosa".
* In 1862, von Recklinghausen reported a tumor of the [[Heart|hear]]<nowiki/>t found in a newborn during autopsy, and by that he is credited to be the first that described the microscopic appearance of tuberous sclerosis.
* Bourneville in 1880, a French neurologist, described the case of a girl who presented at the age of 3 with [[facial eruption]] and died at 15 years of age due to [[epilepsy]], which complicated with [[pneumonia]] and inanition. He found [[brain]] and [[kidney]] tumors on the autopsy which were correctly believed to be the cause of her [[seizures]] and [[mental retardation]].
* In 1911, E. B. Sherlock, superintendent of Belmont Asylum of Idiots, London, coined the word "epiloia" that indicated a clinical triad of epilepsy, low intelligence and [[adenoma sebaceum]].<ref name="pmid389165">{{cite journal| author=Morgan JE, Wolfort F| title=The early history of tuberous sclerosis. | journal=Arch Dermatol | year= 1979 | volume= 115 | issue= 11 | pages= 1317-9 | pmid=389165 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=389165  }}</ref>


Two genetic loci associated with tuberous sclerosis, TSC1 and TSC2, were discovered in 1997 and 1992 respectively.  This has enabled the use of genetic testing as a diagnostic tool.<ref name="TSC-history"/>  The proteins associated with TSC1 and TSC2, harmartin and tuberin, function as a complex in the [[Mammalian target of rapamycin|mTOR]] signalling pathway that controls cell growth and cell division.  The importance of this pathway in cancer therapy has stimulated further research into Tuberous Sclerosis.
In 2002, treatment with [[rapamycin]] was found to be effective at shrinking tumours in animals.  This has led to human trials of rapamycin as a drug to treat several of the tumors associated with Tuberous Sclerosis.<ref name="Rott2005>{{cite web
| url = http://www.tsdev.de/92001/Uploaded/hhehn%7Cgeschichte_der_tsc2005.pdf
| title = Zur Geschichte der Tuberösen Sklerose (The History of Tuberous Sclerosis)
| accessdate = 2007-01-08
| author = Rott HD, Mayer K, Walther B, Wienecke R
| year = 2005
| month = 03
| publisher = Tuberöse Sklerose Deutschland e.V
| language = German
}}</ref>
==References==
==References==
{{Reflist|2}}
[[Category:Genetic disorders]]
[[Category:Genetic disorders]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Neurology]]
[[Category:Neurology]]
[[Category:Needs overview]]
[[Category:Needs overview]]
<references />

Latest revision as of 14:38, 20 July 2020

Tuberous sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Tuberous sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tuberous sclerosis historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tuberous sclerosis historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tuberous sclerosis historical perspective

CDC on Tuberous sclerosis historical perspective

Tuberous sclerosis historical perspective in the news

Blogs on Tuberous sclerosis historical perspective

Directions to Hospitals Treating Tuberous sclerosis

Risk calculators and risk factors for Tuberous sclerosis historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: José Eduardo Riceto Loyola Junior, M.D.[2]

Overview

Tuberous sclerosis is a disease first described in the 19th century. The brain changes were hypothesized to be the cause of the epilepsy and mental retardation only in 1880.

Historical Perspective

  • Tuberous Sclerosis was described as a specific disease in the 19th century, being initially referred to adenoma sebaceum, epiloia, Pringle's disease or Bourneville's disease.
  • Rayer, a French dermatologist, was the one to first describe the disease and the fibrovascular papules that characterize it, making illustrations of it.
  • In 1850 the first written report of tuberous sclerosis appeared in "Vitiligoidea", published by Addison and Gull. It was not recognized as a distinct disease but was classified as "vitiligoidea tuberosa".
  • In 1862, von Recklinghausen reported a tumor of the heart found in a newborn during autopsy, and by that he is credited to be the first that described the microscopic appearance of tuberous sclerosis.
  • Bourneville in 1880, a French neurologist, described the case of a girl who presented at the age of 3 with facial eruption and died at 15 years of age due to epilepsy, which complicated with pneumonia and inanition. He found brain and kidney tumors on the autopsy which were correctly believed to be the cause of her seizures and mental retardation.
  • In 1911, E. B. Sherlock, superintendent of Belmont Asylum of Idiots, London, coined the word "epiloia" that indicated a clinical triad of epilepsy, low intelligence and adenoma sebaceum.[1]

References

  1. Morgan JE, Wolfort F (1979). "The early history of tuberous sclerosis". Arch Dermatol. 115 (11): 1317–9. PMID 389165.